TY - JOUR
T1 - Development of Fluorogenic Substrates of α- L -Fucosidase Useful for Inhibitor Screening and Gene-expression Profiling
AU - Miura, Kazuki
AU - Tsukagoshi, Takumi
AU - Hirano, Takako
AU - Nishio, Toshiyuki
AU - Hakamata, Wataru
N1 - Funding Information:
This work was funded in part by a Sasagawa Scientific Research Grant from The Japan Science Society (grant No. 27–304), JSPS KAKENHI (grant Nos. 26460157 and 17K08375), and a Nihon University College of Bioresource Sciences Research Grant for 2012.
Publisher Copyright:
Copyright © 2019 American Chemical Society.
PY - 2019/9/12
Y1 - 2019/9/12
N2 - Inhibitors of human α-l-fucosidases, tissue α-l-fucosidase (tFuc), and plasma α-l-fucosidase reportedly play roles in multiple diseases, suggesting their therapeutic potential for gastric disease associated with Helicobacter pylori and fucosidosis. Terminal fucose linkages on glycoproteins and glycolipids are a natural substrate for both enzymes; however, there are currently no fluorogenic substrates allowing their cellular evaluation. Here, we described the development of novel three-color fluorogenic substrates for lysosome-localized tFuc that exhibited excellent specificity and sensitivity in three human cell lines. Additionally, we developed a cell-based high-throughput inhibitor screening system in a 96-well format and a cell-based inhibitory activity evaluation system in a 6-well format for tFuc inhibitors using this substrate, which allowed accurate quantification of the inhibition rate. Moreover, analysis of significant changes in gene expression resulting from 30% inhibition of tFuc in HeLa cells revealed potential roles in gastric disease.
AB - Inhibitors of human α-l-fucosidases, tissue α-l-fucosidase (tFuc), and plasma α-l-fucosidase reportedly play roles in multiple diseases, suggesting their therapeutic potential for gastric disease associated with Helicobacter pylori and fucosidosis. Terminal fucose linkages on glycoproteins and glycolipids are a natural substrate for both enzymes; however, there are currently no fluorogenic substrates allowing their cellular evaluation. Here, we described the development of novel three-color fluorogenic substrates for lysosome-localized tFuc that exhibited excellent specificity and sensitivity in three human cell lines. Additionally, we developed a cell-based high-throughput inhibitor screening system in a 96-well format and a cell-based inhibitory activity evaluation system in a 6-well format for tFuc inhibitors using this substrate, which allowed accurate quantification of the inhibition rate. Moreover, analysis of significant changes in gene expression resulting from 30% inhibition of tFuc in HeLa cells revealed potential roles in gastric disease.
KW - DNA microarray
KW - fluorogenic substrate
KW - high-throughput screening
KW - inhibitor
KW - α- l -Fucosidase
UR - http://www.scopus.com/inward/record.url?scp=85072535454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072535454&partnerID=8YFLogxK
U2 - 10.1021/acsmedchemlett.9b00259
DO - 10.1021/acsmedchemlett.9b00259
M3 - Article
AN - SCOPUS:85072535454
SN - 1948-5875
VL - 10
SP - 1309
EP - 1313
JO - ACS Medicinal Chemistry Letters
JF - ACS Medicinal Chemistry Letters
IS - 9
ER -